Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Net Income (2016 - 2026)

Pharma-Bio Serv's Net Income history spans 16 years, with the latest figure at $32860.0 for Q1 2026.

  • For Q1 2026, Net Income rose 284.96% year-over-year to $32860.0; the TTM value through Jan 2026 reached -$85697.0, up 82.8%, while the annual FY2025 figure was -$100463.0, 87.08% up from the prior year.
  • Net Income reached $32860.0 in Q1 2026 per PBSV's latest filing, up from -$102.0 in the prior quarter.
  • In the past five years, Net Income ranged from a high of $526242.0 in Q3 2023 to a low of -$309194.0 in Q3 2024.
  • Average Net Income over 5 years is $86004.9, with a median of $32860.0 recorded in 2026.
  • Peak YoY movement for Net Income: tumbled 163.48% in 2024, then surged 284.96% in 2026.
  • A 5-year view of Net Income shows it stood at $173379.0 in 2022, then crashed by 127.19% to -$47148.0 in 2023, then soared by 134.17% to $16111.0 in 2024, then plummeted by 100.63% to -$102.0 in 2025, then soared by 32315.69% to $32860.0 in 2026.
  • Per Business Quant, the three most recent readings for PBSV's Net Income are $32860.0 (Q1 2026), -$102.0 (Q4 2025), and -$213808.0 (Q3 2025).